Greenwich LifeSciences, Inc. (GLSI) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-99.2%

$0.13

vs $16.46 price

Levered DCF

$0.46

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

2.27

Grey zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-14.69×	-9.28×	-15.25×	-24.92×	-69.51×	-243.13×	-17.24×	-35.71×
P/B	805.09×	160.85×	20.17×	14.85×	11.74×	16.77×	-43.48×	-5.91×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-14.37×	-8.16×	-14.42×	-23.37×	-63×	-233.8×	-17.34×	-35.45×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	1.06×	1.28×	23.74×	51.23×	70.63×	27.41×	0×	0.12×
Debt / equity	0×	0×	0×	0×	0×	0.01×	-0.47×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-5480.5%	-1916.5%	-132.7%	-59.2%	-17.0%	-6.7%	253.6%	16.7%
Return on invested capital	-5505.9%	-1941.1%	-139.2%	-60.8%	-17.1%	-6.7%	478.9%	272.5%
Return on assets	-313.3%	-425.4%	-127.1%	-58.1%	-16.8%	-6.5%	-12842.8%	-1556.6%
Free cash flow yield	-3.5%	-5.0%	-4.8%	-3.2%	-1.4%	-0.2%	-0.5%	-0.2%
Earnings yield	-6.8%	-11.9%	-6.6%	-4.0%	-1.5%	-0.4%	-5.8%	-2.8%
Enterprise value	$278.2M	$142.1M	$128.2M	$182.8M	$287.7M	$434.9M	$59.3M	$59.8M
Net debt / EBITDA	0.32×	0.24×	0.79×	1.72×	5.96×	15.26×	-0.18×	0.05×
Cash conversion cycle (days)	-1,000,106	-283,243	-3,585	-22,317	-22,317	-71,905	-73,902	-28,086